共同社报道,小林制药公司在大阪召开临时股东大会,就大股东香港投资基金“Oasis Management”提出的重新调查“红曲”保健品损害健康问题和任命三名新的外部董事进行讨论。公司方面反对上述提案,与基金方面形成对立,两项议案均被否决。在股东大会的问答环节,Oasis质疑小林制药没有将消费者安全置于首要位置,小林制药反驳指,正与厚生劳动省及大阪府、市一同展开调查,强调已将安全性放在首要位置。根据...
Source Link共同社报道,小林制药公司在大阪召开临时股东大会,就大股东香港投资基金“Oasis Management”提出的重新调查“红曲”保健品损害健康问题和任命三名新的外部董事进行讨论。公司方面反对上述提案,与基金方面形成对立,两项议案均被否决。在股东大会的问答环节,Oasis质疑小林制药没有将消费者安全置于首要位置,小林制药反驳指,正与厚生劳动省及大阪府、市一同展开调查,强调已将安全性放在首要位置。根据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.